Alcohol use curbed by anti-nausea medication, study finds

Jan 25, 2011 By Shari Roan

Alcoholics who were given a medication approved for quelling nausea were able to cut back on their alcohol intake, researchers reported this week. The medication, ondansetron (Zofran), could become a readily available therapy for helping some alcoholics become abstinent.

The study, published Wednesday in the , is based on research on a gene known as 5-HTT that is important to the serotonin system of the brain. Certain variants of this gene can increase the risk of , such as depression, anxiety, obsessive-compulsive disorder and addiction.

Ondansetron is used to prevent nausea and vomiting caused by . But it's in a class of medications that work by blocking serotonin. The study tested the idea that a drug to block this neurotransmitter in genetically susceptible people might reduce the severity of their drinking.

Researchers analyzed the of 283 alcoholics who were still drinking. They found that those with the 5-HTT LL genotype who received ondansetron took fewer drinks per day and had more days of abstinence over the 11-week study compared with people with the LL genotype who did not receive the drug. All the study participants received cognitive-behavioral therapy aimed at helping them become abstinent.

Among the patients who received ondansetron, those with the LL genotype or another variant called LL/TT cut back on their drinking enough to move out of the "high-risk" category of drinkers. But the drug did not seem to help patients who had other forms of the 5-HTT genotype.

The study was led by Bankole A. Johnson, chairman of the department of psychiatry and neurobehavioral sciences at the University of Virginia, and an expert in medications used to treat addiction. His paper on the use of topiramate - an anti-seizure medication - to treat alcoholism was published in the Journal of the American Medical Association in 2007.

In an e-mail, Johnson said that ondansetron had a stronger effect on promoting abstinence than topiramate in the LL genotype group. "Genotyping is becoming more common place and inexpensive," he said, opening the door to tailoring addiction treatment based on an individual's genes.

Explore further: Discount generic drug programs grow over time

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Researchers uncover gene's role in severity of drinking

Feb 04, 2009

New research from the University of Virginia Health System could help explain why some alcoholics are more severe drinkers than others. A UVA team has found strong evidence that the serotonin transporter gene, SLC6A4, plays ...

Scientists identify drug to treat opioid addiction

Feb 17, 2009

Scientists at Stanford University School of Medicine have discovered that a commonly available non-addictive drug can prevent symptoms of withdrawal from opioids with little likelihood of serious side effects. The drug, ondansetron, ...

Gene variant may increase severity of MS

Aug 02, 2010

A new study shows a gene variant may increase the severity of multiple sclerosis (MS) symptoms. The research will be published in the August 3, 2010, issue of Neurology, the medical journal of the American Academy of Neu ...

Recommended for you

Discount generic drug programs grow over time

13 hours ago

Generic discount drug programs (GDDPs, which charge nominal fees to fill prescriptions) have grown over time and their initial lower use by racial/ethnic minorities has evaporated, writes author Song Hee Hong, Ph.D., of the ...

Seniors successfully withdraw from meds

Sep 19, 2014

Elderly people have proved receptive to being de-prescribed medications, as part of a trial aimed at assessing the feasibility of withdrawal of medications among older people.

User comments : 0